Page 1

Strong Q2 with 9 % organic sales growth . Full - year outlook for organic sales and EBIT margin narrowed to high ends of ranges ; ROIC incl . goodwill raised . Organic sales growth of 6 % ( Q2 : 9 % ) in 1H 2021 : Household Care -2 % ( Q2 : -6 % ) ; Food , Beverages & Human Health 14 % ( Q2 : 18 % ) ; Bioenergy 16 % ( Q2 : 54 % ) ; Grain & Tech Processing 17 % ( Q2 : 18 % ) ; Agriculture , Animal Health & Nutrition -9 % ( Q2 : -19 % ) . EBIT margin at 28.6 % ( Q2 : 27.7 % ) . ROIC incl . goodwill at 22.2 % ( Q2 : 20.3 % ) . FCF bef . acq . at DKK 1.8 billion ( Q2 : DKK 1.1 billion ) . Ester Baiget , President & CEO : " We delivered a very satisfactory set of results for the first half of 2021. Although uncertainty related to the pandemic remains and some destocking is still expected in the second half , we narrow the outlook range for organic sales growth upwards to 4 % to 6 % and for the EBIT margin to ~ 26 % . We continue to execute on our strategic direction and today , we reached yet another significant milestone by advancing the strategic opportunity area of Advanced Protein Solutions . We look forward to the upcoming capital markets day in September where we will follow up on our progress and outline strategic priorities to continue driving profitable and sustainable growth . " 1H 2021 In summary : Strong growth in Food , Beverages & Human Health across all subareas . Household Care declined as expected against a high comparator . The Freshness platform and emerging markets contributed positively Strong growth in Bioenergy mainly due to the recovery of the U.S. ethanol production and capacity expansion in Latin America . Strong growth in Grain & Tech Processing led by strong demand for solutions in grain and gradual recovery in textile . Decline in Agriculture , Animal Health & Nutrition mainly due to difficult comparator , BioAg one - off and an expected decline in animal nutrition ● ● ● Strong organic sales growth of 17 % in emerging markets ; developed markets flat Six products launched in the first half , including second quarter launches of yeast and fiber solutions in biofuels and a probiotic solution with immune benefits in human health Strong EBIT margin at 28.6 % despite higher operating costs , currency headwinds and effects of the two recent acquisitions . Strong performance mainly driven by gross margin expansion from operational leverage , supported by timing and one - offs . Free cash flow before acquisitions solid at DKK 1.8 billion and ROIC incl . goodwill was strong at 22.2 % ● Solid balance sheet with NIBD / EBITDA leverage of 0.9x Novozymes reach a significant milestone by advancing the strategic opportunity area of Advanced Protein Solutions ( ann . no . 40 , Aug. 12 , 2021 ) with no financial implications for 2021 other than DKK ~ 300m capex Capital markets day to be held virtually on September 28 , 2021 2021 outlook : Organic sales growth of 4 % to 6 % , with sales in reported DKK slightly less than 1p.p. lower . EBIT margin at ~ 26 % , net supported by one - offs but including negative y / y impacts from currency , as well as M & A related effects of around 1p.p. each . ROIC incl . goodwill between 19 % to 20 % . FCF bef . acq . at DKK 2.5 to 2.9bn now including DKK ~ 300m investment in the new production line in Blair , Nebraska . Novozymes A / S CVR number : 10 00 71 27 Sales performance , organic EBIT margin ROIC , incl . goodwill Free cash flow before acquisitions DKKbn * Includes DKK ~ 300m of additional CAPEX relating to the new production line in Blair , Nebraska . LEI : 529900T6WNZXD2R3JW38 % % 1H 2021 % 6 28.6 22.2 1.8 1H 2020 4 27.5 19.3 2.1 2021 outlook August 12 4 to 6 ~ 26 19 to 20 2.5 to 2.9 * 2021 outlook April 27 2 to 6 25 to 26 ~ 19 2.7 to 3.1 August 12 , 2021 Interim report for 1H 2021 . Company announcement no . 41 Novozymes A / S Krogshoejvej 36 2880 Bagsvaerd Denmark Phone : +45 4446 0000